TY - JOUR
T1 - Renal Function Impairment Below Safety Limits Correlates With Cancer-specific Mortality in Localized Renal Cell Carcinoma
T2 - Results From a Single-center Study
AU - Antonelli, Alessandro
AU - Palumbo, Carlotta
AU - Sandri, Marco
AU - Veccia, Alessandro
AU - Furlan, Maria
AU - Zamboni, Stefania
AU - Francavilla, Simone
AU - Zanotelli, Tiziano
AU - Cozzoli, Alberto
AU - Simeone, Claudio
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2020/8
Y1 - 2020/8
N2 - Background: A recent multi-center study showed how estimated glomerular filtration rate (eGFR) and cancer-specific mortality (CSM) are linearly and inversely related in organ-confined renal cell carcinoma (RCC) whenever the eGFR decreases below specific thresholds. We addressed our previous work limitations related to heterogeneity and missing data, and explored the relationship between eGFR and CSM also in locally advanced RCC. Materials and Methods: All patients with RCC treated with either partial or radical nephrectomy from 1990 to 2018 at a single institution and with complete data on renal function were included. eGFR was managed as a time-dependent variable. The relationship between eGFR and CSM was analyzed using a Fine and Gray multivariable competing risks framework. Subdistribution hazard ratios (SHRs) were calculated accounting for deaths from other causes. Results: Multivariable competing risks analysis showed a “piecewise” relationship between eGFR and CSM, with an inverse linear correlation for eGFR values below 85 mL/min. Below this breakpoint, a significant relationship existed between eGFR and CSM in both clinical (SHR, 1.27; P < .001) and pathologic (SHR, 1.27; P = .001) models in stage I to II RCC subgroup. Conversely, no significance was recorded in this subgroup when considering eGFR values above 85 mL/min. In the stage III to IV subgroup, no significant relationships were recorded, regardless of eGFR values. The retrospective design with inherent biases in data collection represents a limitation. Conclusions: In patients undergoing surgery for stage I to II RCC, preservation of renal function over “safety limits” is protective from CSM.
AB - Background: A recent multi-center study showed how estimated glomerular filtration rate (eGFR) and cancer-specific mortality (CSM) are linearly and inversely related in organ-confined renal cell carcinoma (RCC) whenever the eGFR decreases below specific thresholds. We addressed our previous work limitations related to heterogeneity and missing data, and explored the relationship between eGFR and CSM also in locally advanced RCC. Materials and Methods: All patients with RCC treated with either partial or radical nephrectomy from 1990 to 2018 at a single institution and with complete data on renal function were included. eGFR was managed as a time-dependent variable. The relationship between eGFR and CSM was analyzed using a Fine and Gray multivariable competing risks framework. Subdistribution hazard ratios (SHRs) were calculated accounting for deaths from other causes. Results: Multivariable competing risks analysis showed a “piecewise” relationship between eGFR and CSM, with an inverse linear correlation for eGFR values below 85 mL/min. Below this breakpoint, a significant relationship existed between eGFR and CSM in both clinical (SHR, 1.27; P < .001) and pathologic (SHR, 1.27; P = .001) models in stage I to II RCC subgroup. Conversely, no significance was recorded in this subgroup when considering eGFR values above 85 mL/min. In the stage III to IV subgroup, no significant relationships were recorded, regardless of eGFR values. The retrospective design with inherent biases in data collection represents a limitation. Conclusions: In patients undergoing surgery for stage I to II RCC, preservation of renal function over “safety limits” is protective from CSM.
KW - Cancer specific mortality
KW - Estimated glomerular filtration rate
KW - Partial nephrectomy
KW - Prognosis
KW - Radical nephrectomy
UR - http://www.scopus.com/inward/record.url?scp=85077917527&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2019.12.005
DO - 10.1016/j.clgc.2019.12.005
M3 - Article
SN - 1558-7673
VL - 18
SP - e360-e367
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 4
ER -